真实世界研究中甲氨蝶呤、柳氮磺吡啶与羟氯喹三联疗法对比TNF抑制剂联合甲氨蝶呤治疗类风湿关节炎的结局
基于Corrona类风湿关节炎药物安全性与有效性登记数据库,比较三联疗法(MTX/SSZ/HCQ)与TNFi/MTX联合治疗在RA患者中的真实世界临床有效性和停药情况。经倾向性评分匹配后,三联疗法组停药率更高(生物制剂初治组调整HR 2.17,生物制剂经治组调整HR 1.51),6个月时TNFi/MTX组达到低疾病活动度的比例更高(49.2% vs 33.3%)。
要点
- 真实世界中接受三联疗法的RA患者很少,且三联疗法组停药率显著高于TNFi/MTX组。
- 生物制剂初治患者中,TNFi/MTX组6个月低疾病活动度比例更高(49.2% vs 33.3%)。
- 生物制剂经治患者中,TNFi/MTX组临床结局数值上更优但未达统计学显著。
核心结论
- 在美国真实世界RA患者中,三联疗法(MTX/SSZ/HCQ)的药物持续性和临床有效性均劣于TNFi/MTX联合治疗。
研究设计与样本
- 基于Corrona RA药物安全性与有效性登记数据库的倾向性评分匹配队列研究,匹配比例最高1:3,按生物制剂初治或经治分层。
- 生物制剂初治组:TNFi/MTX 3,926例,三联疗法262例;生物制剂经治组:TNFi/MTX 3,365例,三联疗法130例。
主要发现
- 匹配前三联疗法患者年龄更大、RA病程更长、疾病活动度更低,且恶性肿瘤和其他合并症病史更常见。
- 匹配后93-98%的三联疗法患者可匹配到TNFi/MTX患者,队列特征总体均衡。
- 三联疗法组停药率更高:生物制剂初治组调整HR 2.17(95%CI 1.63-2.88),生物制剂经治组调整HR 1.51(95%CI 1.06-2.15)。
- 6个月时生物制剂初治组达到低疾病活动度的比例TNFi/MTX组为49.2%,三联疗法组为33.3%,差异显著。
- 6个月时CDAI评分平均变化:TNFi/MTX组-9.3单位,三联疗法组-5.5单位(95%CI -1.5, -6.1)。
关键数值与推荐
- 低疾病活动度比例:生物制剂初治组6个月时TNFi/MTX 49.2% vs 三联疗法33.3%。
- CDAI平均变化:TNFi/MTX -9.3单位 vs 三联疗法-5.5单位(95%CI -1.5, -6.1)。
- 停药调整HR:生物制剂初治组2.17(95%CI 1.63-2.88),生物制剂经治组1.51(95%CI 1.06-2.15)。
临床怎么用
- 在考虑三联疗法作为TNFi/MTX替代方案时,应告知患者真实世界中三联疗法的药物持续性和6个月疗效可能较差。
- 对于生物制剂初治的RA患者,TNFi/MTX在6个月低疾病活动度达标方面可能优于三联疗法。
局限性
- 观察性登记研究,尽管采用倾向性评分匹配,仍可能存在未测量混杂。
- 三联疗法组样本量较小(生物制剂初治262例,经治130例)。
- 生物制剂经治组中TNFi/MTX的优势未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Though randomized controlled trials have demonstrated relatively comparable clinical outcomes with triple therapy (methotrexate [MTX], sulfasalazine [SSZ], and hydroxychloroquine [HCQ]) compared to combination therapy (tumor necrosis factor inhibitor [TNFi] and MTX), real-world experiences comparing these strategies have not been well studied. METHODS: We evaluated the clinical effectiveness and effects of medication discontinuation of triple therapy with MTX/SSZ/HCQ versus combination therapy with TNFi/MTX in rheumatoid arthritis (RA) patients enrolled in the Corrona RA Drug Safety & Effectiveness Registry. Propensity score matching was used to match patients up to a ratio of 1:3 to adjust for imbalances between treatment groups, with stratification performed according to biologics-naive or biologics-exposed status of study participants. RESULTS: Patients eligible for analysis in this study included biologics-naive RA patients (3,926 who received combination therapy with TNFi/MTX and 262 who received triple therapy with MTX/SSZ/HCQ) and biologics-exposed RA patients (3,365 who received combination therapy with TNFi/MTX and 130 patients who received triple therapy with MTX/SSZ/HCQ). Before propensity score matching, numerous factors were imbalanced between the treatment groups, with triple therapy patients generally being older, having a longer disease duration of RA and lower RA disease activity, and more likely having a history of malignancy and other comorbidities. After matching, almost all (93-98%) triple therapy patients could be matched to TNFi/MTX therapy patients, and cohort characteristics were generally well balanced. Discontinuation of medication was greater in triple therapy patients referent to TNFi/MTX therapy patients (adjusted hazard ratio [HR] of 2.17 [95% confidence interval 1.63-2.88] in the biologics-naive group; adjusted HR of 1.51 [95% confidence interval 1.06-2.15] in the biologics-exposed group). At 6 months, the proportion of biologics-naive patients attaining low disease activity was significantly greater in the TNFi/MTX treatment group (49.2% in TNFi/MTX therapy patients versus 33.3% in triple therapy patients), as was the mean change in Clinical Disease Activity Index scores (-9.3 units versus -5.5 [95% confidence interval -1.5, -6.1]). Corresponding results in the biologics-exposed patients numerically favored TNFi/MTX therapy compared to triple therapy but did not reach statistical significance. CONCLUSION: Few patients receive triple therapy with MTX/SSZ/HCQ in the US. In the present study, drug persistence and clinical effectiveness outcomes were less favorable in triple therapy patients compared to TNFi/MTX therapy patients.
引用
- Curtis JR, Palmer JL, Reed GW, et al. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021. PMID: 32374918. doi:10.1002/acr.24253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。